Quantcast
Last updated on April 18, 2014 at 12:37 EDT

Latest treatment of multiple sclerosis Stories

2013-11-27 04:21:02

-Sativex® Now Approved in 23 Countries- LONDON, Nov. 27, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that it has received regulatory approval for its prescription medicine Sativex(®) in Switzerland. A full marketing authorization has been granted by the Swissmedic...

2013-11-20 08:26:22

Nevertheless, Injectables Remain First-Line Mainstays Among Newly Diagnosed Patients, According to a New Report from Decision Resources BURLINGTON, Mass., Nov. 20, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, through examination of U.S. patient-level claims data, total patient share of platform injectable disease-modifying therapies (DMTs) among recently treated multiple sclerosis...

2013-11-14 23:04:03

Reportbuyer.com just published a new market research report: Multiple Sclerosis -- KOL Insight and Consensus Outlook Modules. London (PRWEB) November 14, 2013 The multiple sclerosis treatment landscape has undergone dramatic changes over the past year. Biogen’s Tecfidera has revolutionised multiple sclerosis treatment in the U.S., eroding significant market share from older therapies. However, patent concerns has stalled Tecfidera’s launch in Europe. Genzyme have taken advantage of...

2013-10-21 04:21:06

LONDON, Oct. 21, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or the "Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced the successful closing of the European Mutual Recognition Procedure (MRP) in France for Sativex® oromucosal spray in the treatment of spasticity due to Multiple Sclerosis (MS) and a resulting recommendation...

2013-10-02 08:29:56

- New data reinforces the efficacy and safety profile of Sativex® in Multiple Sclerosis Spasticity - LONDON, Oct. 2, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced that data from new MS spasticity studies (clinical trial data, observational study data and registries data collection) is being presented today at the 29(th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. The...

2013-09-30 23:27:33

Reportbuyer.com just published a new market research report: Multiple Sclerosis: KOL Insight. London (PRWEB) September 30, 2013 An incisive report and dynamic analyst briefing service delivering insight from the most influential Multiple Sclerosis (MS) Key Opinion Leaders to map the current treatment landscape and analyse future trends. The past year has seen landmark changes in multiple sclerosis, with the launch of two new novel oral products—Tecfidera (dimethyl fumarate; Biogen...

2013-09-24 08:32:16

Reformulated Copaxone and Lemtrada Are Expected to Bring High Clinical Value, According to a New Report from BioTrends Research Group EXTON, Pa., Sept. 24, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. neurologists report significantly greater overall physician satisfaction with Biogen Idec's recently-launched oral disease-modifying therapy (DMT) Tecfidera than...

2013-09-23 08:27:51

LONDON, Sept. 23, 2013 /PRNewswire/ -- GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced today that agreement for a revised mutually-acceptable reimbursement price for Sativex® has been reached between Almirall S.A., GW's commercial partner in Germany, and the German National Association of Statutory Health Insurance Funds (GKV-SV). This new agreement has resulted in an increase to the previously reduced price imposed by the German authorities in March 2013 which...

2013-09-03 08:29:14

Novel Disease-Modifying Therapies and Reformulations Will Experience Distinct Positioning and Market Access Challenges, According to a New Report from Decision Resources BURLINGTON, Mass., Sept. 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that more than half of surveyed neurologists consider Biogen Idec's Tecfidera to be a breakthrough in the treatment of multiple sclerosis (MS),...

2013-08-14 08:30:14

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- The Tisch MS Research Center of New York announced today that it has received Investigational New Drug (IND) approval from the Food and Drug Administration (FDA) to commence a Phase 1 trial using autologous neural stem cells in the treatment of multiple sclerosis (MS). MS is a chronic human autoimmune disease of the central nervous system that leads to myelin damage and neurodegeneration and affects approximately 2.1 million people worldwide....